BFRI

Biofrontera Inc. NASDAQ Listed Oct 29, 2021

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · biofrontera.us.com

$0.96

-5.59% vs $1.02

Mkt Cap $12.3M

52w Low $0.56 64.3% of range 52w High $1.19

50d MA $0.98 200d MA $0.92

P/E (TTM) —

EV/EBITDA —

P/B 0.9x

Debt/Equity 0.6x

ROE -100.5%

P/FCF -0.9x

RSI (14) 57.40

ATR (14) $0.08

Beta 0.64

50d MA $0.98

200d MA $0.92

Avg Volume 249.6K

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

CIK (SEC)

1858685

Phone

781 245 1325

120 Presidential Way · Woburn, MA 01801 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 19, 2026	AMC	0.29	0.50	+72.4%	0.86	+1.0%	+1.7%	-2.5%	-4.4%	+1.5%	-1.7%	—
Nov 12, 2025	AMC	-0.60	-0.59	+1.7%	0.97	-2.0%	-8.6%	-8.1%	+4.4%	-3.9%	-1.4%	—
Aug 13, 2025	AMC	-0.45	-0.57	-26.7%	0.95	+11.6%	+1.7%	-3.7%	+0.0%	+0.0%	-5.4%	—
May 15, 2025	AMC	-0.14	-0.47	-235.7%	0.70	+1.4%	-7.2%	+3.1%	-1.6%	-2.0%	+3.4%	—
Mar 21, 2025	AMC	0.02	-2.33	-9999.0%	0.86	-1.2%	+4.8%	-0.1%	-1.7%	-4.2%	-4.1%	—
Nov 13, 2024	AMC	-0.73	-0.86	-17.8%	0.83	-5.2%	-15.4%	+4.1%	-8.4%	+14.4%	+1.5%	—
Aug 14, 2024	AMC	-1.19	-1.12	+5.9%	1.14	+12.3%	+1.8%	+17.2%	+2.9%	-9.3%	-4.7%	—
May 15, 2024	AMC	-1.63	-1.85	-13.5%	1.21	-0.8%	-9.9%	-1.8%	+2.8%	+1.8%	+1.8%	—
Mar 15, 2024	AMC	-1.19	-2.33	-95.8%	1.55	+9.0%	-18.7%	-6.3%	+7.6%	-1.6%	-4.0%	—
Nov 9, 2023	AMC	-4.23	-4.64	-9.7%	3.91	-1.5%	-2.6%	+0.5%	+4.2%	-5.8%	+0.8%	—
Aug 11, 2023	AMC	-5.14	-6.14	-19.5%	10.35	-2.2%	-3.2%	-8.3%	+3.4%	-1.6%	-2.5%	—
May 12, 2023	AMC	-4.40	-4.40	+0.0%	8.06	+0.0%	+0.5%	+1.2%	+4.9%	+7.9%	+12.1%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 19	The Benchmark Company	Downgrade	Buy → Speculative Buy	$3	$0.79	$0.78	-1.8%	+1.4%	+0.1%	-3.4%	+3.6%	-1.5%
May 19	Benchmark	Maintains	Buy → Buy	—	$0.65	$0.68	+5.1%	+3.1%	-1.6%	-2.0%	+3.4%	-4.2%
Nov 15	Benchmark	Maintains	Buy → Buy	—	$0.70	$0.75	+5.7%	+4.1%	-8.4%	+14.4%	+1.5%	-2.7%
Aug 16	Benchmark	Maintains	Buy → Buy	—	$1.16	$1.18	+1.7%	+17.2%	+2.9%	-9.3%	-4.7%	+3.3%
Aug 31	Benchmark	Maintains	Buy → Buy	—	$8.87	$8.71	-1.8%	-2.4%	-1.5%	+1.5%	+1.4%	-3.1%
Jul 5	Benchmark	Maintains	Buy → Buy	—	$10.80	$9.74	-9.8%	-12.4%	-6.2%	+5.9%	-1.0%	+5.3%
May 15	Benchmark	Maintains	Buy → Buy	—	$8.06	$8.06	+0.0%	+0.5%	+1.2%	+4.9%	+7.9%	+12.1%

Data updated apr 24, 2026 9:19pm · Source: financialmodelingprep.com